IL-33/ST2 Axis Plays a Protective Effect in Streptococcus pyogenes Infection through Strengthening of the Innate Immunity.
Chih-Feng KuoWei-Yu ChenHai-Han YuYu-Hsuan TsaiYa-Chu ChangChih-Peng ChangNina TsaoPublished in: International journal of molecular sciences (2021)
Group A Streptococcus (GAS) causes invasive human diseases with the cytokine storm. Interleukin-33 (IL-33)/suppression of tumorigenicity 2 (ST2) axis is known to drive TH2 response, while its effect on GAS infection is unclear. We used an air pouch model to examine the effect of the IL-33/ST2 axis on GAS-induced necrotizing fasciitis. GAS infection induced IL-33 expression in wild-type (WT) C57BL/6 mice, whereas the IL-33- and ST2-knockout mice had higher mortality rates, more severe skin lesions and higher bacterial loads in the air pouches than those of WT mice after infection. Surveys of infiltrating cells in the air pouch of GAS-infected mice at the early stage found that the number and cell viability of infiltrating cells in both gene knockout mice were lower than those of WT mice. The predominant effector cells in GAS-infected air pouches were neutrophils. Absence of the IL-33/ST2 axis enhanced the expression of inflammatory cytokines, but not TH1 or TH2 cytokines, in the air pouch after infection. Using in vitro assays, we found that the IL-33/ST2 axis not only enhanced neutrophil migration but also strengthened the bactericidal activity of both sera and neutrophils. These results suggest that the IL-33/ST2 axis provided the protective effect on GAS infection through enhancing the innate immunity.
Keyphrases
- room temperature
- wild type
- early stage
- induced apoptosis
- cell cycle arrest
- poor prognosis
- gene expression
- endothelial cells
- cell death
- escherichia coli
- biofilm formation
- pseudomonas aeruginosa
- cardiovascular disease
- high glucose
- candida albicans
- risk factors
- high throughput
- oxidative stress
- signaling pathway
- single cell
- adipose tissue
- skeletal muscle
- cross sectional
- genome wide
- cystic fibrosis
- immune response
- rectal cancer